The European Commission has approved Celltrion Healthcare’s Herzuma, a biosimilar of Roche/Genentech’s blockbuster Herceptin. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/green_light_for_celltrions_herceptin_biosimilar_1222261ViiV Healthcare has kicked off two late stage studies assessing a potential new regimen for the treatment of HIV-1 infection. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/viiv_kicks_off_phiii_trials_of_hiv_regimen_1177809Teva Pharmaceutical Industries has unveiled plans to buy Allergan-owned US generics giant Anda for $500 million. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/teva_buys_allergans_drug_distribution_group_1090400Shire’s prucalopride is being assessed by regulators in the US as a treatment for chronic idiopathic constipation (CIC). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shires_constipation_drug_under_us_review_1225941Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nice_nod_for_jazz_aml_chemo_1259265Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/daiichi_to_test_cancer_drug_combo_1252985Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/lenvima_wins_green_light_in_liver_cancer_1249253The US Food and Drug Administration has approved Bristol-Myers Squibb's immunotherapy Opdivo as a treatment for the most common form of bladder cancer. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bladder_cancer_nod_for_bms_opdivo_1185762Germany’s Merck is considering the future of its consumer health segment, including a potential full or partial sale of the business as well as new strategic partnerships. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/merck_considers_future_of_consumer_health_unit_1204315Pfizer’s biosimilar of Amgen’s epoetin alfa (Epogen/Procrit) has won backing in the US for approval across all proposed indications. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/pfizers_epogenprocrit_biosimilar_wins_us_backing_1194418
